# Blood-based knee procedures deserve plain answers *Blood-based Choices — Non-surgical Knee Treatment Phoenix* > Learn what PRP means, what remains uncertain, and which questions belong in a non-surgical knee treatment Phoenix visit. The first steps from bed may hurt, even after a fairly good day. When simple care hasn’t helped enough, a blood-based knee procedure may sound worth asking about. This page explains what happens and what the research can’t promise. You deserve a straight answer. ## PRP uses blood drawn from your arm and placed into your knee PRP stands for platelet-rich plasma. Staff draw a small amount of your blood and spin it in a machine. They keep the part with more platelets, the blood cells that gather at a cut. A trained medical provider then places that prepared part into your knee. Nothing in the PRP comes from a donor. The finished mix can vary by clinic, including how many platelets and white cells it holds. That’s why the letters PRP don’t describe one identical product. ## Research does not give one sure amount of relief The largest careful knee test found no clear benefit over salt water at twelve months, while other reports found better movement lasting six to twelve months after PRP. Those findings disagree, so neither one can promise how much better your knee will feel. A clinic ought to explain both results and say which kind of PRP it uses. Research also hasn’t shown that PRP rebuilds cartilage, the slick coat over the bone ends. Feeling better and growing that coat back aren’t the same result. ## Your questions can focus on comfort, walking, and time You might ask whether people hurt less, walked farther, or slept better after the procedure. Ask how long any relief lasted and how many people felt no better. You can also ask about soreness afterward and the price of the whole course. Ask when you’d know the procedure hadn’t helped. The answers should fit your health, medicines, knee exam, and daily needs. Advice from your doctor or a surgeon can help you compare PRP with simpler care. You needn’t decide during the first talk. ## Sources 1. FDA states directly that regenerative medicine therapies - including stem cells, stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes - have NOT been approved for the treatment of any orthopedic condition, naming osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain. FDA further states that being charged for these products, or being offered them outside an FDA-overseen clinical trial, means a patient is likely being deceived and offered a product illegally, and that a product's presence on clinicaltrials.gov or a firm's FDA registration does not mean the product is legally marketed. Reported harms include blindness, tumor formation, neurological events and life-threatening bacterial infections. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Important Patient and Consumer Information About Regenerative Medicine Therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). *FDA.gov*, 2021. 2. FDA's final guidance 'Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use' (July 2020, docket FDA-2017-D-6146, superseding the November 2017 version) sets out FDA's current thinking on the 21 CFR 1271.10(a)(1) minimal-manipulation and 21 CFR 1271.10(a)(2) homologous-use criteria that determine whether a cell or tissue product may be marketed without a biologics licence. Its period of enforcement discretion was extended only through 31 May 2021. US Food and Drug Administration, CBER and CDRH — [Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and Food and Drug Administration Staff](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal). *FDA.gov guidance documents*, 2020. 3. In October 2018 the FTC settled charges that a California physician and two companies he controlled deceptively advertised that 'amniotic stem cell therapy' could treat serious diseases including Parkinson's disease, autism, macular degeneration, cerebral palsy, multiple sclerosis and OSTEOARTHRITIS without competent and reliable scientific evidence. The defendants earned at least USD 3.31 million between 2014 and 2017, with initial injections priced at USD 9,500 to USD 15,000 and follow-up 'booster' treatments at USD 5,000 to USD 8,000. The order imposed a partially suspended USD 3.31 million judgment and required patient notification within 30 days. US Federal Trade Commission, Bureau of Consumer Protection — [FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic](https://www.ftc.gov/news-events/news/press-releases/2018/10/ftc-stops-deceptive-health-claims-stem-cell-therapy-clinic). *FTC.gov press release*, 2018. 4. An assessment of internet-based marketing claims found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States - a phenomenon previously associated with countries with lax medical regulation - leading the authors to conclude that regulatory agencies must better oversee this marketplace. Turner L, Knoepfler P. — [Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.](https://pubmed.ncbi.nlm.nih.gov/27374789/). *Cell Stem Cell*, 2016. DOI: 10.1016/j.stem.2016.06.007. 5. A meta-analysis of 16 randomised trials (807 participants) of intra-articular mesenchymal stem cells for chronic knee pain from osteoarthritis found that at 3-6 months MSC therapy probably produces little to no difference in pain (WMD -0.74cm on a 10cm VAS, 95% CI -1.16 to -0.33, against a minimally important difference of 1.5cm) or physical function, both moderate certainty; at 12 months, probably little to no difference in pain. MSC therapy may increase the risk of any adverse event (RR 2.67, 95% CI 1.19 to 5.99) and of knee pain and swelling (RR 1.58, 95% CI 1.04 to 2.38). Sadeghirad B, Rehman Y, Khosravirad A, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and Cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 6. The RESTORE trial randomised 288 community-based participants aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence grade 2 or 3) to three weekly intra-articular injections of leukocyte-poor PRP or saline placebo, with participants, injectors and assessors all blinded. 93% completed the 12-month follow-up. PRP did not produce a clinically meaningful improvement in knee pain over placebo, and did not slow medial tibial cartilage volume loss on MRI. Bennell KL, Paterson KL, Metcalf BR, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 7. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-poor and leukocyte-rich PRP significantly improved 6-12 month WOMAC function versus placebo (MD -10.54 and -13.20 respectively) and both were superior to hyaluronic acid, with leukocyte-poor PRP ranked first (P-score 0.96) — a materially more favourable read of PRP than the RESTORE trial, which is why this corpus presents both. Journal of Orthopaedic Surgery and Research authors — [Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/41629990/). *Journal of Orthopaedic Surgery and Research*, 2026. DOI: 10.1186/s13018-026-06689-4. 8. A safety review of intra-articular PRP in knee OA found significantly higher rates of mild knee pain and swelling than hyaluronic acid (p<0.001), driven specifically by leukocyte-RICH formulations; leukocyte-poor PRP showed a safety profile similar to HA. No severe adverse events were reported in any group. PM&R authors — [Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared with hyaluronic acid and saline in knee osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/42101047/). *PM&R*, 2026. DOI: 10.1002/pmrj.70141. ## When soreness doesn’t ease, you can ask about a clinic visit At QC Kinetix, a consultation can cover regenerative treatment options, meaning clinic procedures that use material prepared from your own body, for knee soreness. Platelet-rich plasma, called PRP, is one option. Staff draw some of your blood, spin it to gather the platelet-rich part, and prepare it for the knee procedure. A medical provider, meaning a trained clinic staff member, examines your knee and returns that prepared part to the sore joint. You’re welcome to ask what the procedure involves, what relief may be realistic, and what it will cost. The exam may also show that other care would fit you better. The Banner Estrella office is at 9305 W. Thomas Rd., Suite 460. One number serves the area: (602) 837-PAIN. A visit can’t promise a result, and you needn’t choose treatment that day. Book a free consultation: --- A warm welcome and clear knee answers. Help with a sore knee: what may cause it, what can ease it, and when to be seen. A kind welcome, clear knee answers, and practical ways to seek relief. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Banner Estrella, Scottsdale, Peoria and Chandler locations, and those owners benefit when a reader books a consultation. © 2026 Phoenix Knee Ledger. General health education only; an in-person clinician should evaluate your own knee and urgent symptoms.